The estimated Net Worth of Raymond Townsend is at least $271 mil dollars as of 25 September 2018. Raymond Townsend owns over 3,000 units of Kindred Biosciences Inc stock worth over $230,584 and over the last 11 years Raymond sold KIN stock worth over $39,960.
Raymond has made over 13 trades of the Kindred Biosciences Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Raymond sold 3,000 units of KIN stock worth $39,960 on 25 September 2018.
The largest trade Raymond's ever made was exercising 17,561 units of Kindred Biosciences Inc stock on 2 January 2018 worth over $60,585. On average, Raymond trades about 2,338 units every 83 days since 2013. As of 25 September 2018 Raymond still owns at least 24,928 units of Kindred Biosciences Inc stock.
You can see the complete history of Raymond Townsend stock trades at the bottom of the page.
Raymond's mailing address filed with the SEC is C/O KINDRED BIOSCIENCES, INC., 1555 BAYSHORE HIGHWAY, SUITE 200, BURLINGAME, CA, 94010.
Over the last 11 years, insiders at Kindred Biosciences Inc have traded over $10,542,886 worth of Kindred Biosciences Inc stock and bought 50,952,388 units worth $461,948,778 . The most active insiders traders include Animal Health Inc Elanco, West Asset Management Llc Park, eErnest Mario. On average, Kindred Biosciences Inc executives and independent directors trade stock every 34 days with the average trade being worth of $5,949,674. The most recent stock trade was executed by Animal Health Inc Elanco on 27 August 2021, trading 45,508,938 units of KIN stock currently worth $420,957,677.
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
Kindred Biosciences Inc executives and other stock owners filed with the SEC include: